• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

STREAM 阶段 1 短程方案治疗 RR-TB 的失败或复发预测因素。

Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB.

机构信息

St Peter´s Tuberculosis Specialised Hospital/Global Health Committee, Addis Ababa, Ethiopia.

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.

出版信息

Int J Tuberc Lung Dis. 2022 Aug 1;26(8):753-759. doi: 10.5588/ijtld.22.0073.

DOI:10.5588/ijtld.22.0073
PMID:35898125
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9341498/
Abstract

STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the WHO. The present paper analyses factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the Short regimen. This analysis is restricted to 253 participants allocated to the Short regimen and is based on the protocol-defined modified intention to treat (mITT) population. Multivariable Cox regression models were built using backwards elimination with an exit probability of = 0.157, equivalent to the Akaike Information Criterion, to identify factors independently associated with a definite or probable FoR event. Four baseline factors were identified as being significantly associated with the risk of definite or probable FoR (male sex, a heavily positive baseline smear grade, HIV co-infection and the presence of costophrenic obliteration). There was evidence of association of culture positivity at Week 8 and FoR in a second model and Week 16 smear positivity, presence of diabetes and of smoking in a third model. The factors associated with FoR outcomes identified in this analysis should be considered when determining the optimal shortened treatment regimen.

摘要

STREAM(标准化抗结核药物治疗方案)阶段 1 研究表明,与世界卫生组织推荐的长程方案相比,短程方案治疗利福平耐药结核病(RR-TB)的疗效非劣效。本文分析了接受短程方案的参与者中出现治疗失败或复发(FoR)的确定或可能因素。该分析仅限于分配到短程方案的 253 名参与者,并且基于方案定义的修改意向治疗(mITT)人群。使用向后消除法构建多变量 Cox 回归模型,退出概率为 = 0.157,相当于赤池信息量准则,以确定与确定或可能的 FoR 事件独立相关的因素。四个基线因素被确定为与确定或可能的 FoR 风险显著相关(男性、严重阳性基线涂片等级、HIV 合并感染和肋膈角闭塞)。在第二个模型中,第 8 周培养阳性与 FoR 存在关联的证据,在第三个模型中,第 16 周涂片阳性、糖尿病和吸烟的存在与 FoR 存在关联。在这项分析中确定的与 FoR 结局相关的因素应在确定最佳缩短治疗方案时考虑。

相似文献

1
Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB.STREAM 阶段 1 短程方案治疗 RR-TB 的失败或复发预测因素。
Int J Tuberc Lung Dis. 2022 Aug 1;26(8):753-759. doi: 10.5588/ijtld.22.0073.
2
Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial.来自 STREAM 试验的利福平耐药结核病短程方案疗效研究。
BMC Med. 2020 Nov 4;18(1):314. doi: 10.1186/s12916-020-01770-z.
3
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.贝达喹啉-pretomanid-莫西沙星-吡嗪酰胺治疗敏感和耐药肺结核:一项 2c 期、开放标签、多中心、部分随机对照试验。
Lancet Infect Dis. 2024 Sep;24(9):1003-1014. doi: 10.1016/S1473-3099(24)00223-8. Epub 2024 May 17.
4
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial.两种短程标准化方案治疗耐利福平结核病的长期疗效和安全性(STREAM 研究的第二阶段):一项开放标签、多中心、随机、非劣效性试验的延长随访
Lancet Respir Med. 2024 Dec;12(12):975-987. doi: 10.1016/S2213-2600(24)00186-3. Epub 2024 Oct 1.
5
Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis.耐异烟肼结核患者治疗失败和复发的细菌危险因素。
BMC Infect Dis. 2018 Mar 6;18(1):112. doi: 10.1186/s12879-018-3033-9.
6
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.评价两种短程标准化方案治疗利福平耐药结核病(STREAM 阶段 2):一项开放标签、多中心、随机、非劣效性试验。
Lancet. 2022 Nov 26;400(10366):1858-1868. doi: 10.1016/S0140-6736(22)02078-5. Epub 2022 Nov 8.
7
Radiographic characteristics of rifampicin-resistant tuberculosis in the STREAM stage 1 trial and their influence on time to culture conversion in the short regimen.STREET 阶段 1 试验中利福平耐药结核病的放射学特征及其对短程方案中培养物转换时间的影响。
BMC Infect Dis. 2024 Jan 30;24(1):144. doi: 10.1186/s12879-024-09039-z.
8
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].[耐异烟肼或耐利福平结核病的特征及治疗结果]
Kekkaku. 2003 Oct;78(10):611-7.
9
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.《2006年抗结核药物国际共识指南:肺结核、肺外结核及特殊情况结核病的管理》
J Assoc Physicians India. 2006 Mar;54:219-34.
10
Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.药物敏感型肺结核的短程治疗方案与标准方案对比
Cochrane Database Syst Rev. 2019 Dec 12;12(12):CD012918. doi: 10.1002/14651858.CD012918.pub2.

引用本文的文献

1
At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States.终于:美国针对耐多药结核病的简短全口服治疗方案
Open Forum Infect Dis. 2023 Apr 3;10(4):ofad177. doi: 10.1093/ofid/ofad177. eCollection 2023 Apr.

本文引用的文献

1
Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial.来自 STREAM 试验的利福平耐药结核病短程方案疗效研究。
BMC Med. 2020 Nov 4;18(1):314. doi: 10.1186/s12916-020-01770-z.
2
Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis.耐多药结核病和 HIV 成人的死亡率与抗逆转录病毒治疗和抗结核药物使用情况:一项个体患者数据荟萃分析。
Lancet. 2020 Aug 8;396(10248):402-411. doi: 10.1016/S0140-6736(20)31316-7.
3
Poor treatment outcome and its predictors among drug-resistant tuberculosis patients in Ethiopia: A systematic review and meta-analysis.在埃塞俄比亚,耐多药结核病患者的治疗结果不佳及其预测因素:系统评价和荟萃分析。
Int J Infect Dis. 2020 Sep;98:420-439. doi: 10.1016/j.ijid.2020.05.087. Epub 2020 Jul 6.
4
Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries.九个非洲国家耐利福平结核病九个月治疗方案在治疗完成后长达24个月的转归
EClinicalMedicine. 2020 Feb 10;20:100268. doi: 10.1016/j.eclinm.2020.100268. eCollection 2020 Mar.
5
The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis.酒精使用对结核病治疗结果的影响:系统评价和荟萃分析。
Int J Tuberc Lung Dis. 2020 Jan 1;24(1):73-82. doi: 10.5588/ijtld.19.0080.
6
Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence.耐多药结核病的短程治疗方案:十年证据
J Clin Med. 2019 Dec 25;9(1):55. doi: 10.3390/jcm9010055.
7
Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis.预测结核病治疗成功的因素:系统评价与荟萃分析。
PLoS One. 2019 Dec 27;14(12):e0226507. doi: 10.1371/journal.pone.0226507. eCollection 2019.
8
Standardised shorter regimens individualised longer regimens for rifampin- or multidrug-resistant tuberculosis.利福平耐药或耐多药结核病的标准化短程治疗方案与个体化长程治疗方案。
Eur Respir J. 2020 Mar 20;55(3). doi: 10.1183/13993003.01467-2019. Print 2020 Mar.
9
Adverse drug reactions in tuberculosis and management.结核病中的药物不良反应及管理
Indian J Tuberc. 2019 Oct;66(4):520-532. doi: 10.1016/j.ijtb.2019.11.005.
10
Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000-2016.巴西里约热内卢州 2000-2016 年耐多药和广泛耐药结核患者不良治疗结局的预测因素。
PLoS One. 2019 Nov 20;14(11):e0218299. doi: 10.1371/journal.pone.0218299. eCollection 2019.